Profile of:

Liudan Tu

Full name: Liudan Tu

Current country: China

Membership level: Associate

Type of membership: Member

Number of publications: 6

Etanercept/celecoxib on improving MRI inflammation of active ankylosing spondylitis: A multicenter, open-label, randomized clinical trial (2022)

Efficacy and safety of Fengshi Gutong Capsule in patients with active ankylosing spondylitis: A 4-week randomized controlled, double-blinded, double-dummy trial (2022)

A clinical practice guideline for the screening and assessment of enthesitis in patients with spondyloarthritis. (2022)

Active Inflammatory and Chronic Structural Damages of Sacroiliac Joint in Patients With Radiographic Axial Spondyloarthritis and Non-Radiographic Axial Spondyloarthritis. (2021)

Cost of Illness, Quality of Life, and Work Outcomes in Active Ankylosing Spondylitis Patients Treated With Adalimumab in China. (2020)

Costs and work limitation of patients with ankylosing spondylitis in China (2014)